Finally, although mutations in homologous genes BRCA1/BRCA2 increase the risk of pancreatic cancer, they also appear to be associated with better neoadjuvant efficacy, but such data is not committed in the SEER database. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.